Antidepressant treatment and dehydroepiandrosterone sulfate: Different effects of amitriptyline and paroxetine

Neuropsychobiology

Volumn 50, Issue 3, 2004, Pages 252-256

  Deuschle, Michael ^a   Luppa, Peter ^b   Gilles, Maria ^a   Hamann, Bettina ^a   Heuser, Isabella ^a,c  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Dehydroepiandrosterone sulfate hypothalamus pituitary adrenal system; Depression; Selective serotonin reuptake inhibitors; Tricyclic antidepressant

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMITRIPTYLINE; ANDROGEN; ANTIDEPRESSANT AGENT; HYPERICUM EXTRACT; LITHIUM; LORAZEPAM; MIRTAZAPINE; NEUROLEPTIC AGENT; PAROXETINE; PRASTERONE SULFATE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ZOLPIDEM;

ADULT; AGED; ANALYSIS OF VARIANCE; ANDROGEN RELEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MALE; MEDICAL INFORMATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEHYDROEPIANDROSTERONE SULFATE; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE;

EID: 4644367463     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079980     Document Type: Article

References (22)

1. Deuschle M, Schweiger U, Weber B, Gotthardt U, Körner A, Schmider J: Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab 1997;82:234-238.
2. Berr C, Lafont S, Debuire B, Dartigues JF, Baulieu EE: Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological and mental status and shortterm mortality: A French community-based study. Proc Natl Acad Sci USA 1996;93:13410-13415.
3. Michael A, Jenaway A, Paykel ES, Herbert J: Altered salivary dehydroepiandrosterone levels in major depression in adults. Biol Psychiatry 2000;48:989-995.
4. Scott LV, Salahuddin F, Cooney J, Svec F, Dinan TG: Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health. J Affect Disord 1999;54:129-137.
5. Hansen CR, Kroll F, MacKenzie TB: Dehydroepiandrosterone and affective disorders. Am J Psychiatry 1982;139:386-387.
6. Heuser I, Deuschle M, Luppa P, Schweiger U, Standhardt H, Weber B: Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J Clin Endocrinol Metab 1998;83:3130-3133.
7. Takebayashi M, Kagaya A, Uchitomi Y: Plasma dehydroepiandrosterone sulfate in unipolar major depression. J Neural Transm 1998;105:537-542.
8. Tollefson GD, Haus E, Garvey MJ, Evans M, Tuason VB: 24-hour urinary dehydroepiandrosterone sulfate in unipolar depression treated with cognitive and/or pharmacotherapy. Ann Clin Psychiatry 1990;2:39-45.
9. Fabian TJ, Dew MA, Pollock BG, Reynolds CF, Mulsant BH, Butters MA, et al: Endogenous concentrations of DHEA and DHEA-S decrease with remission of depression in older adults. Biol Psychiatry 2001;50:767-774.
10. Romeo E, Strohle A, Spalletta G, di Michele F, Hermann B, Holsboer F, Pasini A, Rupprecht R: Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 1998;155:910-913.
11. Maayan R, Yagorowski Y, Grupper D, Weiss M, Shtaif B, Kaoud MA; Weizman A: Basal plasma dehydroepiandrosterone sulfate level: A possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients. Biol Psychiatry 2000;48:693-701.
12. Schüle C, di Michele F, Baghai T, Romeo E, Bernardi G, Zwanzger P, Padberg F, Pasini A, Rupprecht R: Influence of sleep deprivation on neuroactive steroids in major depression. Neuropsychopharmacology 2003;28:577-581.
13. Deuschle M, Hamann B, Meichel C, Krumm B, Lederbogen F, Kniest A, Heuser I: Antidepressive treatment with amitriptyline and paroxetine: Effects upon saliva cortisol concentrations. J Clin Psychopharmacol 2003;23:201-205.
14. Inder WJ, Prickett TC, Mulder RT, Donald RA, Joyce PR: Reduction in basal afternoon plasma ACTH during early treatment of depression with fluoxetine. Psychopharmacology 2001;156:73-78.
15. Parker LN, Odell WD: Control of adrenal androgen secretion. Endocr Rev 1980;1:392-410.
16. Heuser I, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, Yassouridis A, Holsboer F: Pituitary adrenal system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and healthy controls. Am J Psychiatry 1996;153:93-99.
17. Nickel T, Sonntag A, Schill J, Zobel A, Ackl N, Brunnauer A, Murck H, Ising M, Yassouridis A, Steiger A, Zihl J, Holsboer F: Clinical and neurobiological effects of tianeptine and paroxetine in major depression. J Clin Psychopharmacol 2003;23:155-168.
18. Wolkowitz OM, Reus VI: Treatment of depression with antiglucocorticoid drugs. Psychosom Med 1999;61:698-711.
19. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, Roberts E: Doubleblind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999;156:646-649.
20. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR: Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry 1999;45:1533-1541.
21. Goodyer IM, Herbert J, Altham PME: Adrenal secretion during major depression in 8 to 16 year olds. 3. Influence of cortisol/DHEA ratio at presentation on subsequent rates of disappointing life events and persistent major depression. Psychol Med 1998;28:265-273.
22. Kroboth PD, Salek FS, Stone RA, Bertz RJ, Kroboth FJ: Alprazolam increases dehydroepiandrosterone concentrations. J Clin Psychopharmacol 1999;19:114-124.